Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

In this study, researchers found that cayenne leaf extract significantly enhanced hair length and quantity in mice, with a 10% concentration being the most effective for stimulating growth.

This study demonstrated that the pharmacokinetic profiles of finasteride and doxazosin remain bioequivalent when administered in combination compared to when each drug is taken alone.

This study found that finasteride reduced impulsivity in a rat model of pramipexole-induced probability discounting, possibly by normalizing D3 receptor expression in the nucleus accumbens.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

This article discusses frontal fibrosing alopecia as a type of Lichen planopilaris marked by gradual hair loss at the front of the scalp but reports no new clinical results.

Tailored medication preparation and ongoing education are crucial for effective treatments.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

Tofacitinib might be used to treat hair loss.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

In this study, pantothenic acid at 20 μg/ml was observed to promote dermal papilla cell proliferation and migration, likely through up-regulation of ID3 and inhibition of Notch signaling.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This article reviews the use of anti-androgens, particularly cyproterone acetate, for managing hirsutism, but does not provide new clinical results.

This case report describes a patient who experienced rapid hair depigmentation after starting pazopanib for metastatic renal cell carcinoma, which may suggest therapy success despite being distressing.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This study found that PRP treatment showed better results than injectable minoxidil for reducing hair loss and promoting hair growth, with noticeable effects after the second application.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

This study found that nanocapsules formulated as a dispersion and applied with massage may enhance follicular uptake of clobetasol propionate while minimizing its skin penetration, offering a potential improvement over conventional treatments for scalp diseases.

This study found that phenyl-imidazole sulfonamide derivatives, particularly ISCK03, inhibited c-kit signaling and promoted depigmentation in various experimental settings, suggesting potential use as skin-whitening agents.

This paper presents a case where alopecia was associated with the use of escitalopram and improved after switching to duloxetine, alongside a literature review of antidepressant-related alopecia.

This study suggests that a low daily dose of finasteride may be effective in reducing recurrent priapism episodes in children and adolescents with sickle cell disease, though larger controlled studies are needed to confirm these findings.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.